The study of the new treatment for children with the fragile bone disease Osteogenesis Imperfecta was published this week in the world’s leading general medical journal, The Lancet.
This is the first study to clearly demonstrate that the use of the medicine risedronate can not only reduce the risk of fracture in children with brittle bones but also have rapid action – the curves for fracture risk begin to diverge after only 6 weeks of treatment.
Nick Bishop, Professor of Paediatric Bone Disease at the University of Sheffield, said: “We wanted to show that the use of risedronate could significantly impact on children’s lives by reducing fracture rates – and it did.
“The fact that this medicine can be given by mouth at home (other similar medicines are given by a drip in hospital) makes it family-friendly.”
The study, funded by the Alliance for Better Bone Health, trialled children with Osteogenesis Imperfecta aged 4-15 years and showed that oral risedronate reduced the risk of first and recurrent clinical fractures and that the drug was generally well tolerated.
To read the published article in The Lancet, titled Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial, visit The Lancet.
For more information about osteogenesis imperfecta, visit the Brittle Bone Society.
The University of Sheffield
With nearly 25,000 of the brightest students from 117 countries coming to learn alongside 1,209 of the world’s best academics, it is clear why the University of Sheffield is one of the UK’s leading universities. Staff and students at Sheffield are committed to helping discover and understand the causes of things – and propose solutions that have the power to transform the world we live in.
A member of the Russell Group, the University of Sheffield has a reputation for world-class teaching and research excellence across a wide range of disciplines. The University of Sheffield has been named University of the Year in the Times Higher Education Awards 2011 for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen’s Anniversary Prizes (1998, 2000, 2002, 2007), recognising the outstanding contribution by universities and colleges to the United Kingdom’s intellectual, economic, cultural and social life.
One of the markers of a leading university is the quality of its alumni and Sheffield boasts five Nobel Prize winners among former staff and students. Its alumni have gone on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Research partners and clients include Boeing, Rolls-Royce, Unilever, Boots, AstraZeneca, GSK, Siemens, Yorkshire Water, and many more household names, as well as UK and overseas government agencies and charitable foundations.
The University has well-established partnerships with a number of universities and major corporations, both in the UK and abroad. The White Rose University Consortium (White Rose) is a strategic partnership between 3 of the UK’s leading research universities of Leeds, Sheffield and York. Since its creation in 1997 White Rose has secured more than £100M into the Universities.
For further information please contact:
Media Relations Officer
The University of Sheffield
0114 222 1046